| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Solid TumorSEQ(TM)
Test Code14309
CPT Codes
0379U
Preferred Specimen
1 block Tissue.
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** Ship ambient or on ice pack in summer. For FFPE and
__slides a pathology report must be submitted with sample.
__Do not reject.
__
__Submit tissue in sterile biohazard plastic bag.
Collection Instructions:
__** This test is not available for Wyoming patient testing.
__** Ship ambient or on ice pack in summer. For FFPE and
__slides a pathology report must be submitted with sample.
__Do not reject.
__
__Submit tissue in sterile biohazard plastic bag.
Minimum Volume
Tissue: 1 block
Unstained slides: 5 slides
Unstained slides: 5 slides
Other Acceptable Specimens
10 slides Unstained slides
Transport Container
Tissue: Paraffin embedded tissue block
Unstained slides: Slide holder
Unstained slides: Slide holder
Transport Temperature
Tissue and Unstained slides: Room temperature preferred;
_Refrigerated acceptable; Frozen unacceptable
_Refrigerated acceptable; Frozen unacceptable
Specimen Stability
Tissue or Unstained slides
__Room temperature: Acceptable
__Refrigerated: Acceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
__Room temperature: Acceptable
__Refrigerated: Acceptable
__Frozen: Unacceptable
__-70 Degrees: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject, send to labratory for, testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
A.M. Sets up 3 days a week.
Report Available
Reports in 8 to 11 days.
Clinical Significance
The 523-gene comprehensive genomic profiling panel is
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient s
tumor tissue. This comprehensive panel offers the
opportunity for a broader scope of genomic information
compared to single gene tests or smaller panels. For
example, it may be useful for patients with limited or
ill-defined treatment options and for those considering
clinical trials. This panel uses next-generation sequencing
to detect mutations present in DNA and RNA extracted from
formalin-fixed, paraffin embedded (FFPE) tissue sections of
solid tumors. The test is designed to detect single
nucleotide variants (SNVs) and small insertions/deletions,
as well as whole-gene copy number alterations,
translocations, and splice site variants in a select group
of genes. Microsatellite instability (MSI) and tumor
mutation burden (TMB) are also evaluated.
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient s
tumor tissue. This comprehensive panel offers the
opportunity for a broader scope of genomic information
compared to single gene tests or smaller panels. For
example, it may be useful for patients with limited or
ill-defined treatment options and for those considering
clinical trials. This panel uses next-generation sequencing
to detect mutations present in DNA and RNA extracted from
formalin-fixed, paraffin embedded (FFPE) tissue sections of
solid tumors. The test is designed to detect single
nucleotide variants (SNVs) and small insertions/deletions,
as well as whole-gene copy number alterations,
translocations, and splice site variants in a select group
of genes. Microsatellite instability (MSI) and tumor
mutation burden (TMB) are also evaluated.
